AMENDMENTS TO THE CLAIMS

1. (original) An 8-oxoadenine compound shown by the formula (1):

wherein ring A represents a 6-10 membered aromatic carbocyclic ring or a 5-10 membered heteroaromatic ring;

R represents a halogen atom, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkoxy group, a haloalkoxy group, a maino group, an alkylamino group, a dialkylamino group, or a cyclic amino group:

n represents an integer of 0-2, and when n is 2, the Rs may be the same or different;

 Z^1 represents a substituted or unsubstituted alkylene group or a substituted or unsubstituted cycloalkylene group;

 X^2 represents oxygen atom, sulfur atom, SO₂, NR⁵, CO, CONR⁵, NR⁵CO, SO₂NR⁵, NR⁵SO₂, NR⁵CONR⁶ or NR⁵CSNR⁶ (in which R⁵ and R⁶ are each independently hydrogen atom, a substituted or unsubstituted alkyl group, and a substituted or unsubstituted cycloalkyl group);

Y¹, Y² and Y³ represent each independently a single bond or an alkylene group;

 X^1 represents oxygen atom, sulfur atom, SO_2 , NR^4 (wherein R^4 is hydrogen atom or an alkyl group) or a single bond;

R² represents hydrogen atom, a substituted or unsubstituted alkyll group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group or a substituted or unsubstituted cycloalkyl group; and

R¹ represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group, a haloalkyl group, a haloalkoxy group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted cycloalkyl group, or its pharmaceutically acceptable salt.

Docket No.: 0020-5516PUS1

2. (previously presented) The 8-oxoadenine compound according to claim 1, wherein ring A represents a 6-10 membered aromatic carbocyclic ring, or a 5-10 membered heteroaromatic ring containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms;

R represents a halogen atom, an alkyl group of 1-6 carbons, a hydroxyalkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a hydroxyalkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, a mino group, an alkylamino group of 1-6 carbons, a dialkylamino group in which each alkyl moiety has 1-6 carbons, and a cyclic amino group;

n is an integer of 0-2, and when n is 2, Rs may be the same or different;

 Z^1 represents an alkylene group of 1-6 carbons or a cycloalkylene group of 3-8 carbons, which is optionally substituted by hydroxy group;

X² represents oxygen atom, sulfur atom, SO₂, NR⁵, CO, CONR⁵, NR⁵CO, SO₂NR⁵, NR⁵SO₂, NR⁵CONR⁶ or NR⁵CONR⁶ (in which R⁵ and R⁶ are independently hydrogen atom, a substituted or unsubstituted alkyl group of 1-6 carbons, and a substituted or unsubstituted cycloalkyl group of 3-8 carbons, wherein the substituents of the alkyl group or cycloalkyl group are selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, carboxy group, an alkoxycarbonyl group of 2-5 carbons, carboxyl group, amino group, an alkylamino group of 1-6 carbons, a cyclic amino group, carboxyl group and tetrazolyl group which may be substituted by an alkyl group of 1-6 carbons):

 Y^1 , Y^2 and Y^3 represent each independently a single bond or an alkylene group of 1-6 carbons; X^1 represents oxygen atom, sulfur atom, SO_2 , NR^4 (wherein R^4 represents hydrogen atom or an alkyl group) or a single bond;

9

R² represents a substituted or unsubstituted alkyl group of 1-6 carbons, a substituted or unsubstituted alkenyl group of 2-6 carbons, a substituted or unsubstituted alkenyl group of 2-6 carbons or a substituted or unsubstituted cycloalkyl group of 3-8 carbons (wherein the substitutent in the alkyl group, alkenyl group and alkynyl group is selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an acyloxy group of 2-10 carbons, amino group, an alkylamino group of 1-6 carbons, a dialklylamino group in which the each alkyl moiety has 1-6 carbons, and a cyclic amino group); and

R¹ represents hydrogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an alkoxycarbonyl group of 2-5 carbons, a haloalkyl group of 1-6 carbons, a haloalkoxy group of 1-6 carbons. a substituted or unsubstituted aryl group of 6-10 carbons, a substituted or unsubstituted 5-10 membered heteroaryl group containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms, or a substituted or unsubstituted cycloalkyl group of 3-8 carbons:

and the said substituent in the aryl group, the heteroaryl group and the cycloalkyl group is selected from a halogen atom, hydroxy group, an alkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons, amino group, an alkylcarbonyl group of 2-5 carbons, amino group, an alkylcarbonyl group of 1-6 carbons and a dialkylamino group (wherein the each alkyl group has 1-6 carbons).

and the said cyclic amino group represents a 4-7 membered saturated cyclic amino group containing 1-2 hetero atoms selected from 1-2 nitrogen atoms, 0-1 oxygen atom and 0-1 sulfur atom, which may be substituted with a halogen atom, hydroxy group, oxo group, an alkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons or an alkoxycarbonyl group of 2-5 carbons,

or its pharmaceutically acceptable salt.

 (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 or 2, wherein X² is oxygen atom, sulfur atom, NR⁵, SO₂, NR⁵SO₂ or NR⁵CONR⁶.

 (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Y³ is a single bond, methylene or ethylene.

- 5. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Z¹ is a straight chained alkyelne group of 1-6 carbons which may be substituted with hydroxy group.
- (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein X¹ is oxygen atom or sulfur atom.
- (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein Y¹ is a single bond or an alkylene group of 1-6 carbons.
- 8. (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein R¹ is hydrogen atom, an alkoxycarbonyl group, hydroxy group, or an alkoxy group.
- (previously presented) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1, wherein a group shown by the formula (2) in the formula (1):

(wherein ring A, R, n, Y³ and R² have the same meaning as in claim 1)

$$(R)_n$$
 $(R)_n$ $(R)_n$ $(R)_n$ $(R)_n$

(wherein R, n and R² have the same meaning as in claim 1, and R³ is hydrogen atom or an alkyl group).

10. (Original) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9, wherein R² is methyl group or an alkyl group of 2-6 carbons substituted by a dialkylamino group or a cyclic amino group.

11. (Original) The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9 or 10, wherein R³ is hydrogen atom.

12. (previously presented) A pharmaceutical composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient.

13. (previously presented) An composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim las an active ingredient, wherein said composition has immuno-modulatory activity.

14. (previously presented) A composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient, wherein said composition has antiviral, anticancer or anti-allergy activity.

15. (previously presented) A composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 as an active ingredient, wherein said composition is formulated for topical administration.

16-18. (canceled)

- 19. (previously presented) A method for modulating immune response which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1.
- 20. (previously presented) A method for treating or preventing viral diseases, cancers and allergic diseases which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1.
- 21. (previously presented) A process for preparing the 8-oxoadenine compound according to claim 1 which comprises brominating a compound shown by the formula (10):

$$\begin{array}{c|c}
 & NH_2 \\
 & N \\
 & N$$

wherein ring A, n, R, R^1 , R^2 , X^1 , X^2 , Y^1 , Y^2 , Y^3 and Z^1 are the same defined in the claim 1,

reacting the resultant of the bromination with a metal alkoxide and then hydrolyzing, or hydrolyzing the resultant of the bromination.

22. (Original) A compound shown by the formula (10):

1.

wherein ring A, n, R, R¹, R², X^1 , X^2 , Y^1 , Y^2 , Y^3 and Z^1 are the same defined in the claim

23. (previously presented) A process for preparing the 8-oxoadenine compound according to claim 1 which comprises deprotecting a compound shown by the formula (11):

$$R^{1}$$
 X^{1} X^{1} X^{1} X^{1} X^{1} X^{1} X^{2} X^{2} X^{2} X^{2} X^{3} X^{3

wherein ring A, n, R, R I , R 2 , X 1 , X 2 . Y 1 , Y 2 , Y 3 and Z I are the same defined in the claim 1.

24. (Original) A compound shown by the formula (11):

$$R^{1}$$
 X^{1} X^{1} X^{1} X^{1} X^{1} X^{1} X^{1} X^{2} X^{2} X^{2} X^{2} X^{3} X^{3

wherein ring A, n, R, R^1, R^2, X^1, X^2, Y^1, Y^2, Y^3 and Z^1 are the same defined in the claim 1.

25. (Currently amended) A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of the following compounds:

- 2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-{2-[4-(2-methoxycarbonylethyl)phenoxy]ethyl} adenine,
- 2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylbenzenesulfonamide)butyl]adenine,
- 2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylmethylbenzenesulfonamide)butyl]adenine,
- 2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylphenylaminocarbonylamino)butyl]adenine,
- 2-Butoxy-8-oxo-9-[4-(3-methoxycarbonylmethylphenylaminocarbonylamino)butyl]adenine,

Methyl [3-({[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yi)ethyl]amino}methyl)phenyl]acetate,

 $[3-(\{[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl] amino\} methyl) phenyl] acetic acid.$

Methyl 3-({[3-(6-mino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

 $yl) propyl] amino \} methyl) benzoate,\\$

3-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyi]amino}methyl)benzoic acid,

Methyl 4-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino}methyl)benzoate,

4-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}methyl)benzoic acid,

15

Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-9H-purin-9-yl)propyl](2-morpholin-4-

ylethyl)amino]methyl)phenyl)acetate,

Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yi)butyl]amino)methyl)phenyl]acetate,

Ethyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethoxy]benzoate,

3-(Dimethylamino)propyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

```
vi)ethoxylbenzoate.
Methyl 3-[4-([[4-(6-amino-2-butoxy-8-oxo-7.8-dihydro-9H-purin-9-
yl)butyl]amino}sulfonyl)phenyl|propanoate.
3-[4-([4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
vl)butvl]amino}sulfonyl)phenyl|propanoic acid,
Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-
pyrrolidin-1-vlethyl)amino[sulfonyl] phenyl)acetate.
(3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-pyrrolidin-1-
ylethyl)aminolsulfonyl)phenyl)acetic acid,
Methyl (3-4[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-v])butyl)(2-
methoxyethyl)amino sulfonyl) phenyl)acetate,
(3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)buty]](2-
methoxycthyl)amino]sulfonyl)phenyl)acetic acid,
Methyl (3-11[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
yl)butyl](methyl)amino]sulfonyl)phenyl)acetate,
(3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
yl)butyl](methyl)amino]sulfonyl)phenyl)acetic acid,
Methyl [3-(1[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-
(dimethylamino)-2,2-dimethylpropyllamino) sulfonyl)phenyllacetate.
[3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl}butyl][3-(dimethylamino)-2,2-
dimethylpropyllamino) sulfonyl) phenyllacetic acid.
Methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
yl)propyl]amino}sulfonyl)phenyllacetate.
Methyl
              (3-1[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxy-2-
methylpropyi)amino|sulfonyl|phenyl)acetate,
(3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-hydroxy-2-
methylpropyl)amino[sulfonyl] phenyl)acetic acid,
Methyl [3-(1[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
vi)ethyllamino}sulfonyl)phenyllacetate.
```

```
Methyl
                  [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-v1)butv1][(2R)-2,3-
dibydroxypropyllamino) sulfonyl)phenyllacetate,
[3-(1]4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-vI)butvIII(2R)-2,3-
dihydroxypropyllamino\sulfonyl)phenyllacetic acid,
Methyl 3-({[4-(6-amino-2-butoxy-8-oxo-7.8-dihydro-9H-purin-9-v]}butyl][3-
(dimethylamino)-2,2-dimethylpropyllamino) sulfonyl)benzoate.
3-([[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][[3-(dimethylamino)-2,2-
dimethylpropyllamino) sulfonyl) benzoic acid.
Methyl (3-1[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-v])butyl](3-
morpholin-4-ylpropyl)aminolmethyl)phenyl)acetate,
(3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](3-morpholin-4-
ylpropyl)amino|methyl|phenyl)acetic acid,
Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-
(dimethylamino)-2,2-dimethylpropyllamino methyl)phenyl acetate,
[3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-
dimethylpropyllamino) methyl)phenyllacetic acid,
Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl){3-(2-
oxopyrrolidin-1-vl)propyllamino}methyl)phenyllacetate.
13-{{14-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyll[3-(2-oxopyrrolidin-1-
vl)propyllamino{methyl)phenyllacetic acid.
Methyl (3-1][4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-
morpholin-4-vlethyl)amino methyl) phenyl)acetate.
(3-1114-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl)(2-morpholin-4-
ylethyl)aminolmethyl)phenyl)acetic acid.
Methyl (3-[[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-v1)propyl](3-
morpholin-4-ylpropyl)amino|methyl|phenyl)acetate,
Methyl [3-(1[4-(6-artino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-vl)butvl)[2-(1]-
tetrazol-5-vl)ethvllamino|methvl)phenvllacetate.
Methyl (3-1/2-(6-amino-2-butoxy-8-oxo-7.8-dihydro-9H-purin-9-
```

```
yl)ethyl]thio{phenyl)acetate,
```

(3-{[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl]thio{phenyl)acetic acid,

Methyl (3-1/2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)ethyl]amino]phenyl)acetate,

Methyl (3-{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino)phenyl)acetate,

(3-{[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]amino}phenyl)acetic acid,

Methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino)methyl)phenyl]acetate,

([3-({[3-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)propyl]amino}methyl)phenyl]acetic acid,

Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](2-

methoxyethyl)amino]methyl}phenyl)acetate,

(3-{[[2-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)ethyl](2-

methoxyethyl)amino]methyl}phenyl)acetic acid,

Methyl (3-{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)ethyl]sulfonyl)phenyl)acetate,

Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)ethyl](methyl)amino]methyl}phenyl)acetate,

 $(3-\{[[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-4]\}) - (3-(2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-4)) - (3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-4)) - (3-(6-Amino-2-butoxy-8-oxo-7)) - (3-(6-Amino-2-butoxy-8-oxo-7))$

yl)ethyl](methyl)amino]methyl}phenyl)acetic acid,

Methyl 4-[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)-2-

hydroxypropoxy]benzoate,

Methyl (3-{{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](2-

hydroxyethyl)amino]methyl}phenyl)acetate,

Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl](2-

18

hydroxyethyl)amino]methyl)phenyl)acetate.

2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylmethylphenoxy)ethyl]adenine,

- 2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylphenoxy)ethyl]adenine, 2-Butoxy-8-oxo-9-[2-(2-hydorxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(2-hydroxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-hydroxycarbonylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylmethylphenoxy)ethyl]adenine; 2-Butoxy-8-oxo-9-[2-(4-hydroxycarbonylmethylphenoxy)ethyl]adenine,
- 2-Butoxy-8-oxo-9-{2-[4-(2-hydroxycarbonyolethyl)phenoxy]ethyl}adenine,
- 2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylbenzenesulfonamide)butyl]adenine,
- 2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylmethylbenzenesulfonamide)butyi]adenine,
- 2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylphenylaminocarbonylamino)butyl]adenine and
- 2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylmethylphenylaminocarbonylamino)butyl]adenine.